Mettler-Toledo International Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited, compared with the three months ended March 31, 2022. Mettler-Toledo supplies precision instruments and related services across laboratory, industrial, and retail markets.
Financial performance
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Net sales | $928.7 million | $897.8 million | +3% reported; +7% in local currencies |
| Gross profit / margin | $546.6 million / 58.9% | $519.6 million / 57.9% | Margin +1.0 percentage point |
| Earnings before taxes | $226.6 million | $213.0 million | +6% |
| Net earnings | $188.4 million | $174.0 million | +8% |
| Diluted EPS | $8.47 | $7.55 | +12% |
| Operating cash flow | $153.3 million | $90.8 million | +$62.4 million |
Product sales increased 1% in U.S. dollars and 5% in local currencies; service revenue increased 11% and 15%, respectively. Gross-margin improvement reflected favorable price realization, partly offset by higher costs, mix, and currency. SG&A was nearly flat in reported dollars, while R&D rose 6%. Interest expense increased to $18.2 million from $11.3 million, reflecting higher variable rates and additional borrowings. The reported tax rate was 16.9%, versus 18.3%.
Cash, debt, and liquidity
- Cash and cash equivalents were $89.1 million at March 31, down from $96.0 million at December 31, 2022. Operating cash flow was $153.3 million; capital expenditures were $23.2 million.
- Total debt was $2.123 billion, including $107.1 million classified as current and $2.016 billion long term. The company reported $595.1 million of additional availability under its credit agreement and compliance with debt covenants.
- Cash flow from operations improved year over year, with working-capital movements contributing; cash-flow changes included lower inventory and receivables, offset by reductions in payables and accruals.
- Share repurchases totaled $250.0 million for 166,628 shares, at an average $1,511.78 per share. Remaining authorization was $3.2 billion. Shareholders’ equity was negative $24.5 million at quarter-end.
Business changes and management commentary
- Revenue grew across most regions and businesses. Local-currency sales increased 6% in the Americas and Europe and 10% in Asia/Rest of World, including 9% growth in China.
- Laboratory sales grew 5% in local currencies, with pipette products declining amid customer inventory reductions. Industrial sales grew 7% in local currencies; food retailing sales grew 36%, supported by project activity in the Americas and Europe.
- Chinese Operations’ external-customer sales grew 9% in local currencies, but total segment sales fell 6% in U.S. dollars and segment profit declined 4%, partly due to currency and lower intersegment sales. Management noted difficult prior-year comparisons ahead.
- Management cited broad-based demand, sales and marketing execution, product innovation, and margin-expansion and cost-saving initiatives. It also cautioned that economic conditions and end markets are uncertain and may change quickly.
Outlook, risks, and unusual items
- The filing provides no specific numerical full-year revenue or earnings guidance. Management states Q1 results are not necessarily indicative of full-year 2023 performance and expects available cash, operating cash flow, and credit capacity to meet foreseeable needs.
- Key risks cited include recession and end-market uncertainty, inflation, developments related to Ukraine, foreign-exchange movements, and potential changes in customer demand. A 1% strengthening of the Swiss franc against the euro is estimated to reduce annual pretax earnings by $1.9–$2.1 million; a 1% weakening of the Chinese renminbi against the U.S. dollar by $3.8–$4.3 million.
- In March, the company issued $150 million of 5.45% senior notes due 2033, using proceeds to refinance debt and for general corporate purposes. A $50 million senior note matures in September 2023.
- Restructuring charges were $4.3 million, mainly employee-related. The company recorded $1.9 million of excise tax on net share repurchases under the Inflation Reduction Act and expects the Act’s overall financial impact to be immaterial.
- Management does not expect pending legal proceedings, including environmental matters, to have a material adverse effect. No material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Whether sales growth and margin gains persist, particularly given pipette inventory reductions and challenging China comparisons.
- Debt refinancing and interest-rate exposure, including the September 2023 maturity and the effect of variable rates on interest expense.
- Cash conversion and working-capital trends; Q1 operating cash flow benefited from period-specific balance changes.
- The pace and funding of share repurchases relative to cash generation, debt levels, and the company’s negative reported shareholders’ equity.
- Foreign-exchange, inflation, recession, and Ukraine-related exposures, and whether management’s stated currency sensitivities remain representative.